Literature DB >> 21326105

Vasodilation in response to the GPR30 agonist G-1 is not different from estradiol in the mRen2.Lewis female rat.

Sarah H Lindsey1, Kyle A Carver, Eric R Prossnitz, Mark C Chappell.   

Abstract

Our studies in the mRen2.Lewis female rat, an angiotensin II- and estrogen-dependent model of hypertension, revealed that chronic activation of estrogen receptor GPR30 markedly reduces blood pressure in ovariectomized females. The present studies measured acute vasodilation to the selective GPR30 agonist G-1 and 17-β-estradiol (10(-9)-10(-5.5) M) in isolated aortic rings and mesenteric arteries from intact mRen2.Lewis females. Maximal relaxation was greater in mesenteric vessels versus the aorta for both G-1 (47% ± 8% vs 80% ± 5% of phenylephrine preconstriction, P < 0.001) and estradiol (42% ± 7% vs 83% ± 4% of phenylephrine preconstriction, P < 0.001). The GPR30 antagonist G15 attenuated the response to both estradiol and G-1. Removal of the endothelium or pretreatment with Nitro-L-arginine methyl ester (L-NAME) partially attenuated vasorelaxation. Responses were not altered in mesenteric vessels from ovariectomized females. Immunohistochemical analysis revealed GPR30 expression in mesenteric endothelial and smooth muscle cells, and smooth muscle expression was confirmed in cultured cells. We conclude that estradiol-induced relaxation in conduit and resistance vessels from mRen2.Lewis females may be mediated by the novel estrogen receptor GPR30. The direct vasodilatory response of G-1 in resistance vessels presents one mechanism for the reduction in blood pressure induced by chronic G-1 administration.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21326105      PMCID: PMC3095760          DOI: 10.1097/FJC.0b013e3182135f1c

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  41 in total

1.  Estrogen or the AT1 antagonist olmesartan reverses the development of profound hypertension in the congenic mRen2. Lewis rat.

Authors:  Mark C Chappell; Patricia E Gallagher; David B Averill; Carlos M Ferrario; K Bridget Brosnihan
Journal:  Hypertension       Date:  2003-07-21       Impact factor: 10.190

2.  Acute gender-specific hemodynamic and inotropic effects of 17beta-estradiol on rats.

Authors:  M E Beyer; G Yu; H Hanke; H M Hoffmeister
Journal:  Hypertension       Date:  2001-11       Impact factor: 10.190

3.  Estradiol alters nitric oxide production in the mouse aorta through the alpha-, but not beta-, estrogen receptor.

Authors:  B Darblade; C Pendaries; A Krust; S Dupont; M-J Fouque; J Rami; P Chambon; F Bayard; J-F Arnal
Journal:  Circ Res       Date:  2002-03-08       Impact factor: 17.367

4.  Comparable vasorelaxant effects of 17alpha- and 17beta-oestradiol on rat mesenteric resistance arteries: an action independent of the oestrogen receptor.

Authors:  E K Naderali; A B Walker; P Doyle; G Williams
Journal:  Clin Sci (Lond)       Date:  1999-12       Impact factor: 6.124

5.  Increased magnitude of relaxation to oestrogen in aorta from oestrogen receptor beta knock-out mice.

Authors:  B O Nilsson; E Ekblad; T Heine; J A Gustafsson
Journal:  J Endocrinol       Date:  2000-08       Impact factor: 4.286

6.  17Beta-estradiol inhibits high-voltage-activated calcium channel currents in rat sensory neurons via a non-genomic mechanism.

Authors:  Dong Yun Lee; Young Gyu Chai; Eunhee B Lee; Ki Whan Kim; Seung-Yeol Nah; Tae Hwan Oh; Hyewhon Rhim
Journal:  Life Sci       Date:  2002-03-15       Impact factor: 5.037

7.  Endothelium-dependent relaxation by G protein-coupled receptor 30 agonists in rat carotid arteries.

Authors:  Brad R S Broughton; Alyson A Miller; Christopher G Sobey
Journal:  Am J Physiol Heart Circ Physiol       Date:  2010-01-08       Impact factor: 4.733

8.  Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial.

Authors:  Jacques E Rossouw; Garnet L Anderson; Ross L Prentice; Andrea Z LaCroix; Charles Kooperberg; Marcia L Stefanick; Rebecca D Jackson; Shirley A A Beresford; Barbara V Howard; Karen C Johnson; Jane Morley Kotchen; Judith Ockene
Journal:  JAMA       Date:  2002-07-17       Impact factor: 56.272

9.  Inflammatory biomarkers, hormone replacement therapy, and incident coronary heart disease: prospective analysis from the Women's Health Initiative observational study.

Authors:  Aruna D Pradhan; JoAnn E Manson; Jacques E Rossouw; David S Siscovick; Charles P Mouton; Nader Rifai; Robert B Wallace; Rebecca D Jackson; Mary B Pettinger; Paul M Ridker
Journal:  JAMA       Date:  2002-08-28       Impact factor: 56.272

10.  Estrogen plus progestin and the risk of coronary heart disease.

Authors:  JoAnn E Manson; Judith Hsia; Karen C Johnson; Jacques E Rossouw; Annlouise R Assaf; Norman L Lasser; Maurizio Trevisan; Henry R Black; Susan R Heckbert; Robert Detrano; Ora L Strickland; Nathan D Wong; John R Crouse; Evan Stein; Mary Cushman
Journal:  N Engl J Med       Date:  2003-08-07       Impact factor: 91.245

View more
  55 in total

1.  Long- but not short-term estradiol treatment induces renal damage in midlife ovariectomized Long-Evans rats.

Authors:  Margaret A Zimmerman; Dillion D Hutson; Emma H Trimmer; Shreya N Kashyap; Jennifer L Duong; Brennah Murphy; Elin M Grissom; Jill M Daniel; Sarah H Lindsey
Journal:  Am J Physiol Renal Physiol       Date:  2016-11-09

2.  Role of GPER in estrogen-dependent nitric oxide formation and vasodilation.

Authors:  Natalie C Fredette; Matthias R Meyer; Eric R Prossnitz
Journal:  J Steroid Biochem Mol Biol       Date:  2017-05-18       Impact factor: 4.292

3.  Molecular pharmacology of GPCRs.

Authors:  Christopher J Langmead; Roger J Summers
Journal:  Br J Pharmacol       Date:  2018-11       Impact factor: 8.739

Review 4.  What have we learned about GPER function in physiology and disease from knockout mice?

Authors:  Eric R Prossnitz; Helen J Hathaway
Journal:  J Steroid Biochem Mol Biol       Date:  2015-07-16       Impact factor: 4.292

5.  The putative G-protein coupled estrogen receptor agonist G-1 suppresses proliferation of ovarian and breast cancer cells in a GPER-independent manner.

Authors:  Cheng Wang; Xiangmin Lv; Chao Jiang; John S Davis
Journal:  Am J Transl Res       Date:  2012-10-10       Impact factor: 4.060

6.  Reduced vasorelaxation to estradiol and G-1 in aged female and adult male rats is associated with GPR30 downregulation.

Authors:  Sarah H Lindsey; Ariel S da Silva; Mauro S Silva; Mark C Chappell
Journal:  Am J Physiol Endocrinol Metab       Date:  2013-05-14       Impact factor: 4.310

7.  Estrogen protects renal endothelial barrier function from ischemia-reperfusion in vitro and in vivo.

Authors:  Michael P Hutchens; Tetsuhiro Fujiyoshi; Radko Komers; Paco S Herson; Sharon Anderson
Journal:  Am J Physiol Renal Physiol       Date:  2012-05-23

8.  Subtype-specific estrogen receptor-mediated vasodilator activity in the cephalic, thoracic, and abdominal vasculature of female rat.

Authors:  Ossama M Reslan; Zongzhi Yin; Graciliano R A do Nascimento; Raouf A Khalil
Journal:  J Cardiovasc Pharmacol       Date:  2013-07       Impact factor: 3.105

Review 9.  Estrogen and the female heart.

Authors:  A A Knowlton; D H Korzick
Journal:  Mol Cell Endocrinol       Date:  2014-01-22       Impact factor: 4.102

10.  GPER/GPR30 and Regulation of Vascular Tone and Blood Pressure.

Authors:  Matthias R Meyer; Eric R Prossnitz; Matthias Barton
Journal:  Immunol Endocr Metab Agents Med Chem       Date:  2011
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.